Inclusion Criteria:

1. Histologically-confirmed diagnosis of Barrett's metaplasia within 12 months prior to trial entry. Note: The presence of LGD may be subject to disagreement between pathologists. This will not affect trial entry, since patients with or without LGD are eligible to participate. All cases in which there is disagreement regarding the presence of LGD will be reviewed by a third pathologist for histological classification prior to the efficacy analysis.
2. Cases of short-segment (less than or equal to 3cm) Barrett's esophagus must be large enough to allow adequate sampling of tissue without completely resecting the metaplasia.
3. Age greater than or equal to 18 years.
4. ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%)
5. Participants must have normal organ and marrow function as defined below: Leukocytes greater than or equal to 3,000/UL; Absolute neutrophil count greater than or equal to 1,500/UL; Platelets greater than or equal to 100,000/UL; Total bilirubin within normal institutional limits; AST (SGOT)/ALT (SGPT) less than or equal to institutional ULN; Creatinine within normal institutional limits. Alkaline phosphatase less than or equal to the institutional ULN.
6. Willingness to abstain from all tea consumption while on the study drug.
7. Willingness to record intake of caffeine-containing foods and medications while on the study. A significant portion of caffeine intake occurs from "hidden" sources, including medications and foods. Study subjects will be provided a list of permissible medications, beverages and foods which contain caffeine.
8. Participants may continue therapy with proton pump inhibitors, nonsteroidal anti-inflammatory agents, and celecoxib or rofecoxib.
9. Pregnancy testing to within 2 weeks prior to randomization. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. If a female participant does become pregnant while on study, she will be removed from the study.
10. Willingness to comply with all treatment and follow-up procedures.
11. Willingness to wait at least one month since last endoscopic evaluation.
12. Ability to understand and willingness to sign a written informed consent document.
13. Inclusion of Women and Minorities. Both men and women and members of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

1. Histologically confirmed high-grade dysplasia.
2. Histologically confirmed diagnosis of invasive carcinoma of the esophagus.
3. Prior endoscopic therapy for Barrett's esophagus, including mucosal ablation, resection and esophagectomy, and photodynamic therapy.
4. History of esophageal strictures with moderate-to-severe dysphagia or odynophagia that may interfere with ingestion/swallowing of the study drug. Trial participation will be determined by the study investigator after consideration of other factors including severity of dysphagia and odynophagia, necessity for treatment of strictures, and nutritional status.
5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Poly E.
6. Participants may not be receiving any other investigational agents within 30 days prior to randomization or during the study.
7. Use of medications, herbs, and vitamin and mineral supplements that contain tea compounds should not be taken while participating in the study and on study drug and for 30 days prior to trial entry. If patients are consuming any of these items and would like to participate in this study, then a 30-day voluntary washout will be required.
8. Uncontrolled or significant co-morbid illness including, but not limited to, active or serious infection requiring intravenous antibiotics; symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia; active gastrointestinal bleeding; predisposing condition to gastrointestinal bleeding (including but not limited to gastritis, diverticulitis, colitis, and hemorrhoids); active malignancy diagnosed or treated within 5 years, except for squamous cell carcinoma of the skin, basal cell carcinoma of the skin, carcinoma in situ,
9. Continued from # 8. Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery and/or radiation therapy, Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery; patients receiving active chemotherapy or radiation; or psychiatric illness/social situations that would limit compliance with study requirements.
10. Participants will not take aspirin, aspirin-containing substances, coumadin (warfarin), heparin, or iron for 5 days before each endoscopy.